This is the heart and soul of the web site. Here we have literally tens of thousands of posts dating back over a decade. These are listed in reverse chronological order. You can also click on any category icon to see posts tagged with that particular category.
Stan and I are doing our monthly free public webinar on the Big Five and Sectors after the close tonight and we’ll be looking at AMZN, AAPL, FB, NFLX, TSLA, IBB, IYR, XLE, XLF, XLK and XRT. If you’d like to attend you can register for that on our April Free Webinars page. We are also of course doing our monthly free public Chart Chat on Sunday and you can register for that on the same page.
The possible triangle resistance on SPX broke and ES and SPX have both broken their respective IHS trendlines at the highs today, so all of ES/SPX, NQ/NDX and TF/RUT have now broken up from their IHS necklines. This is the inflection point I was looking at in Chart Chat on Sunday and if this is going to be a Janus bear flag reversal, then I’d expect a failure here or not too much higher. If the IHSes are for real then the respective targets on SPX/NDX and RUT would be in the 2792, 6920 and 108 areas respectively. I’ll be taking the bull targets seriously if SPX reaches 2712. Intraday Video from theartofchart.net – Update on ES, NQ and TF: (more…)
The General Electric train wreck continues – – – if we get into a bear market, I assume this will become a penny stock. Anyway, here’s the recent performance during one of the biggest bull runs in human history, fueled by trillions of dollars of free central bank money:
Biotech stocks we follow were big movers Tuesday, and here are four to watch for continued upside.
REGENXBIO Inc. (RGNX) exploded up 18%, or $5.95, to close at $37.40 on very heavy volume of 1.2 million shares traded Tuesday. That is more than three times its average volume. The move was a follow-through from Monday’s surge that came on news that business partner, AveXis (AVXS), also in the gene therapy space, is being acquired by Novartis. Next target is $40-41.
Tandem Diabetes Care, Inc. (TNDM) tore up 22%, or $1.29, closing at $7.01 on huge volume of 6.6 million shares traded. That is more than four times its average volume. The move came as the medical device company announced preliminary financial results indicating insulin pump shipments increased by 56 percent and sales by 42 percent in the first quarter of 2018 compared the first quarter of 2017. Having moved up with high velocity, the stock has appreciated a whopping 89% in value in the last three weeks. On March 23, Robert W. Baird upgraded the stock from neutral to outperform with a price target lifted from $3 to $7. Price is at the top of its channel, so expect a potential short-term pullback. Next target: $8.50. (more…)